Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 33
Filter
1.
Catheter Cardiovasc Interv ; 103(5): 731-735, 2024 Apr.
Article in English | MEDLINE | ID: mdl-38494678

ABSTRACT

Catheter kinking is not an uncommon scenario during cardiac catheterization via transradial access in patients with tortuous vascular anatomy. Several noninvasive and invasive methods have been described to unkink and retrieve the kinked catheter out of the vessel. We present a novel mother-daughter technique to retrieve a kinked radial artery catheter.


Subject(s)
Mothers , Radial Artery , Female , Humans , Radial Artery/diagnostic imaging , Nuclear Family , Coronary Angiography , Treatment Outcome , Catheters , Cardiac Catheterization/methods
2.
Am J Cardiol ; 150: 15-23, 2021 07 01.
Article in English | MEDLINE | ID: mdl-34006375

ABSTRACT

Chronic kidney disease (CKD) in patients with ST-elevation myocardial infarction (STEMI) is associated with worse outcomes. We assessed the impact of CKD on guideline directed coronary revascularization and outcomes among STEMI patients. The Nationwide Inpatient Sample dataset from 2012-2014 was used to identify patients with STEMI using International Classification of Diseases, Ninth Revision, Clinical Modification codes. Patients were categorized as non-CKD, CKD without dialysis, and CKD with dialysis (CKD-HD). Outcomes were revascularization, death and acute renal failure requiring dialysis (ARFD). A total of 534,845 were included (88.9% non-CKD; 9.6% CKD without dialysis, and 1.5% CKD-HD). PCI was performed in 77.4% non-CKD, 56.2% CKD without dialysis, and 48% CKD-HD patients (p < 0.0001). In-hospital mortality and ARFD were significantly higher in CKD patients (16.5% and 40.6%) compared with non-CKD patients (7.12% and 7.17%) (p < 0.0001). In-hospital mortality was significantly lower in patients treated revascularization compared with patients treated medically (non-CKD: adjusted odds ratio (aOR) 0.280, p < 0.0001; CKD without dialysis: aOR 0.39, p < 0.0001; CKD-HD: aOR 0.48, p < 0.0001). CKD was associated with higher length of hospital stay and cost (5.86 ± 13.97, 7.57 ± 26.06 and 3.99 ± 11.09 days; p < 0.0001; $25,696 ± $63,024, $35,666 ± $104,940 and $23,264 ± $49,712; p < 0.0001 in non-CKD, CKD without dialysis and CKD-HD patients respectively). In conclusion, CKD patients with STEMI receive significantly less PCI compared with patients without CKD. Coronary revascularization for STEMI in CKD patients was associated with lower mortality compared to medical management. The presence of CKD in patients with STEMI is associated with higher mortality and ARFD, prolonged hospital stay and higher hospital cost.


Subject(s)
Myocardial Revascularization , Percutaneous Coronary Intervention , Renal Insufficiency, Chronic/complications , ST Elevation Myocardial Infarction/surgery , Acute Kidney Injury/etiology , Adult , Aged , Aged, 80 and over , Cross-Sectional Studies , Female , Hospital Costs/statistics & numerical data , Hospital Mortality , Humans , Length of Stay/statistics & numerical data , Male , Middle Aged , Prognosis , Renal Dialysis , Renal Insufficiency, Chronic/mortality , Renal Insufficiency, Chronic/therapy , ST Elevation Myocardial Infarction/mortality , United States/epidemiology
3.
Catheter Cardiovasc Interv ; 98(6): 1177-1184, 2021 11 15.
Article in English | MEDLINE | ID: mdl-33856107

ABSTRACT

OBJECTIVES: To assess the outcomes following transcatheter edge-to-edge mitral valve repair (TMVr) in patients with chronic kidney disease (CKD). BACKGROUND: Percutaneous TMVr is beneficial in high surgical risk patients with severe mitral regurgitation (MR). However, those with CKD are not well studied. METHODS: Utilizing the International Classification of Disease (ninth and tenth revision, clinical modification codes) and the Nationwide Inpatient Sample database, we identified 9,228 patients who underwent TMVr during 2010-2016, including those with no or mild CKD (group 1, n = 6,654 [72.11%]), moderate or severe CKD (group 2, n = 2,125 [23.03%]) and end-stage renal disease (ESRD) on dialysis (group 3, n = 449 [4.86%]). In-hospital clinical outcomes, length of stay and cost were assessed. RESULTS: In-hospital mortality increased numerically as CKD severity increased, but not statistically different between groups (1.8, 3.3, and 4.5% respectively in group 1, 2, and 3, p = .07). Moderate to severe CKD (group 2) was an independent predictor of acute renal failure requiring hemodialysis (ARFD) (OR: 3.51, CI: 2.33-5.28, p < .0001), the composite outcome of death, ARFD or stroke [OR: 3.15, 95% CI: 2.10-4.76, p < .0001] and extended length of stay [OR: 1.73, 95% CI: 1.24-2.42), p = .001] while ESRD (group 3) was an independent predictor of higher hospital cost [OR: 1.66, 95% CI: 1.01-2.74), p = .04] as compared with no or mild CKD (group 1). CONCLUSIONS: High surgical risk patients with severe MR commonly have associated comorbidities including CKD. TMVr outcomes appear to worsen with worsening CKD and therefore careful clinical case selection and further studies evaluating TMVr outcomes in CKD patients is warranted.


Subject(s)
Heart Valve Prosthesis Implantation , Mitral Valve Insufficiency , Renal Insufficiency, Chronic , Cardiac Catheterization/adverse effects , Heart Valve Prosthesis Implantation/adverse effects , Hospitals , Humans , Inpatients , Mitral Valve/diagnostic imaging , Mitral Valve/surgery , Mitral Valve Insufficiency/epidemiology , Mitral Valve Insufficiency/surgery , Renal Insufficiency, Chronic/diagnosis , Renal Insufficiency, Chronic/epidemiology , Treatment Outcome
4.
Article in English | MEDLINE | ID: mdl-31241442

ABSTRACT

INTRODUCTION: Bivalirudin and heparin are the two most commonly used anticoagulants used during Percutaneous Coronary Intervention (PCI). The results of Randomized Controlled Trials (RCTs) comparing bivalirudin versus heparin monotherapy in the era of radial access are controversial, questioning the positive impact of bivalirudin on bleeding. The purpose of this systematic review is to summarize the results of RCTs comparing the efficacy and safety of bivalirudin versus heparin with or without Glycoprotein IIb/IIIa Inhibitors (GPI). METHODS: This systematic review was performed in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses PRISMA statements for reporting systematic reviews. We searched the National Library of Medicine PubMed, Clinicaltrial.gov and the Cochrane Central Register of Controlled Trials to include clinical studies comparing bivalirudin with heparin in patients undergoing PCI. Sixteen studies met inclusion criteria and were reviewed for the summary. FINDINGS: Several RCTs and meta-analyses have demonstrated the superiority of bivalirudin over heparin plus routine GPI use in terms of preventing bleeding complications but at the expense of increased risk of ischemic complications such as stent thrombosis. The hypothesis of post- PCI bivalirudin infusion to mitigate the risk of acute stent thrombosis has been tested in various RCTs with conflicting results. In comparison, heparin offers the advantage of having a reversible agent, of lower cost and reduced incidence of ischemic complications. CONCLUSION: Bivalirudin demonstrates its superiority over heparin plus GPI with better clinical outcomes in terms of less bleeding complications, thus making it as anticoagulation of choice particularly in patients at high risk of bleeding. Further studies are warranted for head to head comparison of bivalirudin to heparin monotherapy to establish an optimal heparin dosing regimen and post-PCI bivalirudin infusion to affirm its beneficial effect in reducing acute stent thrombosis.


Subject(s)
Acute Coronary Syndrome/drug therapy , Anticoagulants/therapeutic use , Antithrombins/therapeutic use , Heparin/therapeutic use , Peptide Fragments/therapeutic use , Percutaneous Coronary Intervention/methods , Female , Hirudins , Humans , Male , Randomized Controlled Trials as Topic , Recombinant Proteins/therapeutic use , Treatment Outcome
5.
Cardiovasc Revasc Med ; 21(4): 501-507, 2020 04.
Article in English | MEDLINE | ID: mdl-31377129

ABSTRACT

BACKGROUND: Percutaneous coronary intervention (PCI) outcomes for patients with significant calcification have been consistently inferior compared to patients without significant calcification. Procedural success and long-term outcomes after PCI have been worse in patients with severe coronary calcium. OBJECTIVE: A Bayesian meta-analysis of outcomes comparing rotational atherectomy (RA) with orbital atherectomy (OA) was performed. METHODS: PubMed, Embase, and Cochrane Library databases were searched through 30th November 2018 and identified 4 observational studies. RESULTS: The primary end-point, Major Adverse Cardiac Event (MACE) composing of death, MI and stroke at 1 year was more likely with RA (OR = 1.61; 95% CI: 1.11-2.33; p = 0.01) as compared to OA. The driver of the difference in MACE between the two groups was a statistically significant difference in mortality favoring OA (OR = 4.65; 95% CI: 1.36-15.87; p = 0.01). Peri-procedural MI, the other component of the primary end-point was 1.3 times more likely in the RA arm (OR = 1.35; 95% CI 0.95-1.92; p-0.09) and was not statistically different between the groups. The odds of a vascular complication were not different in the two groups (OR = 1.26; 95% CI: 0.73-2.17; p = 0.41). In an adjusted Bayesian analysis, mortality (OR = 3.69; 95% CI: 0.30-38.51), MACE (OR = 1.68; 95% CI: 0.55-5.49), MI (OR = 1.42; 95% CI: 0.50-4.29) and dissections/perforations (OR = 0.38; 95% CI: 0.10-1.38) were not different in RA and OA groups. CONCLUSION: Our study is the first published Bayesian meta-analysis comparing MACE and peri-procedural outcomes in RA compared to OA. These findings lay the foundation for a randomized comparison between the two competing technologies.


Subject(s)
Atherectomy, Coronary , Coronary Artery Disease/therapy , Percutaneous Coronary Intervention , Vascular Calcification/therapy , Atherectomy, Coronary/adverse effects , Atherectomy, Coronary/mortality , Bayes Theorem , Coronary Artery Disease/diagnostic imaging , Coronary Artery Disease/mortality , Coronary Artery Disease/physiopathology , Humans , Percutaneous Coronary Intervention/adverse effects , Percutaneous Coronary Intervention/mortality , Risk Factors , Severity of Illness Index , Treatment Outcome , Vascular Calcification/diagnostic imaging , Vascular Calcification/mortality , Vascular Calcification/physiopathology
7.
Cardiovasc Revasc Med ; 20(3): 241-247, 2019 03.
Article in English | MEDLINE | ID: mdl-30030065

ABSTRACT

INTRODUCTION: Over the recent years, there has been increased interest in the use of transradial (TR) access for percutaneous coronary intervention (PCI), including rotational atherectomy (RA). However, a large proportion of operators seem to be reluctant to use TR access for complex PCI including rotational atherectomy for heavily calcified coronary lesions. METHODS: We searched MEDLINE, ClinicalTrials.gov and the Cochrane Library for studies comparing radial versus femoral access in patients undergoing RA. Studies were included if they reported at least one of the following outcomes in each group separately: major adverse cardiac events (MACE), major bleeding, stent thrombosis, myocardial infarction (MI), hospital length of stay, radiation exposure, procedure time, procedure success and all-cause mortality. Odds ratio (OR) or mean difference (MD) with 95% confidence interval (CI) were calculated and a p-value of <0.05 was considered as a level of significance. RESULTS: This meta-analysis included 5 retrospective studies with 3315 patients undergoing RA via radial access and 5838 patients via femoral access. Radial access was associated with lower major access site bleeding (OR: 0.45, 95% CI: 0.31-0.67, p < 0.001), and radiation exposure (MD: -16.1, 95%CI: -25.4--6.7 Gy cm2, p = 0.0007). There were no significant differences observed in all-cause in-hospital mortality (OR: 0.92, 95% CI: 0.69-1.23, p = 0.58); MACE (OR: 0.80, CI: 0.63, 1.02, p = 0.08), stent thrombosis (OR: 0.28, 95%CI: 0.06-1.33 p = 0.11); and MI (OR: 0.43, 95%CI: 0.15-1.24, p = 0.12). There were no significant differences in hospital stay, procedure time or procedure success between the two groups (p > 0.05). CONCLUSION: This meta-analysis of 9153 patients from observational studies demonstrates similar all-cause mortality, MACE, procedural success and procedural time during RA performed using TR access and TF access. However, TR access was associated with decreased access site bleeding and radiation exposure. Given the observational nature of these findings, a randomized controlled trial is warranted for further evidence.


Subject(s)
Atherectomy, Coronary , Catheterization, Peripheral , Coronary Artery Disease/therapy , Femoral Artery , Radial Artery , Vascular Calcification/therapy , Aged , Aged, 80 and over , Atherectomy, Coronary/adverse effects , Atherectomy, Coronary/mortality , Catheterization, Peripheral/adverse effects , Catheterization, Peripheral/mortality , Coronary Artery Disease/diagnostic imaging , Coronary Artery Disease/mortality , Female , Femoral Artery/diagnostic imaging , Humans , Male , Middle Aged , Observational Studies as Topic , Punctures , Radial Artery/diagnostic imaging , Risk Assessment , Risk Factors , Treatment Outcome , Vascular Calcification/diagnostic imaging , Vascular Calcification/mortality
8.
Cureus ; 11(3): e4299, 2019 Mar 22.
Article in English | MEDLINE | ID: mdl-32190431

ABSTRACT

Transcatheter aortic valve replacement (TAVR) is now the preferred choice of treatment for severe symptomatic aortic stenosis (AS) patients who are at intermediate to high risk for surgery. Rare complications like valve embolization have been described and we report a case with unique cause for such complication. A 79-year-old female presented with new onset dyspnea on exertion for evaluation and work up to the outside hospital and was found to have severe AS and referred to us for TAVR evaluation. She had a history of coronary artery bypass grafts surgery and bioprosthetic mitral valve replacement (MVR) 10 years ago. Preoperative transesophageal echocardiogram (TEE) revealed normally functioning bioprosthetic mitral valve and severe AS with peak/mean gradients of 67/44 mm Hg. She underwent transfemoral TAVR using a 26-mm Edwards Sapien S3 TAVR valve. During the slow deployment of the TAVR valve while rapid pacing, the valve appeared to move a little. Shortly after the removal of the delivery system out of the valve, the TAVR valve embolized to ascending aorta. It was carefully withdrawn into the aortic arch past the great vessels with an inflated balloon aortic valvuloplasty (BAV) catheter. Then, BAV was performed x 2 to plan for TAVR with a second valve, but the BAV balloon water-melon seeded repeatedly. We concluded that in this case, the rigid struts of bioprosthetic mitral valve encroaching on LVOT resulted in TAVR valve embolization and a decision was made to abort further attempts at TAVR valve implantation. This patient later under surgical aortic valve replacement (SAVR) and is clinically doing well at six months of clinical follow-up.

9.
Cardiovasc Revasc Med ; 20(9): 758-767, 2019 09.
Article in English | MEDLINE | ID: mdl-30503811

ABSTRACT

BACKGROUND: Drug eluting stents (DES) are preferred over bare metal stents (BMS) for native coronary artery revascularization unless contraindicated. However, the preferred stent choice for saphenous venous graft (SVG) percutaneous coronary interventions (PCI) is unclear due to conflicting results. METHODS: PubMed, Clinical trials registry and the Cochrane Center Register of Controlled Trials were searched through June 2018. Seven studies (n = 1639) comparing DES versus BMS in SVG-PCI were included. Endpoints were major adverse cardiac events (MACE), cardiovascular mortality, all-cause mortality, myocardial infarction (MI), target vessel revascularization (TVR), target lesion revascularization (TLR), in-stent thrombosis, binary in-stent restenosis, and late lumen loss (LLL). RESULTS: Overall, during a mean follow up of 32.1 months, there was no significant difference in the risk of MACE, cardiovascular mortality, all-cause mortality, MI, stent thrombosis, TVR and TLR between DES and BMS. However, short-term follow up (mean 11 months) showed lower rate of MACE (OR 0.66 [0.51, 0.85]; p = 0.002), TVR (OR 0.47 [0.23, 0.97]; p = 0.04) and binary in-stent restenosis (OR 0.14 [0.06, 0.37]; p < 0.0001) in DES as compared with BMS. This benefit was lost on long-term follow up with a mean follow up 35.5 months. CONCLUSION: In this meta-analysis of SVG-PCI, DES use was associated with similar MACE, cardiovascular mortality, all-cause mortality, MI, in-stent thrombosis, TVR and TLR compared with BMS during long-term follow up. There was high incidence of MACE noted in both DES and BMS suggesting a need for exploring novel strategies to treat SVG disease to improve clinical outcomes.


Subject(s)
Coronary Artery Bypass/adverse effects , Coronary Artery Disease/surgery , Drug-Eluting Stents , Graft Occlusion, Vascular/therapy , Metals , Percutaneous Coronary Intervention/instrumentation , Saphenous Vein/transplantation , Stents , Coronary Artery Bypass/mortality , Coronary Artery Disease/mortality , Coronary Artery Disease/physiopathology , Coronary Thrombosis/etiology , Coronary Thrombosis/mortality , Graft Occlusion, Vascular/etiology , Graft Occlusion, Vascular/mortality , Graft Occlusion, Vascular/physiopathology , Humans , Percutaneous Coronary Intervention/adverse effects , Percutaneous Coronary Intervention/mortality , Prosthesis Design , Randomized Controlled Trials as Topic , Risk Assessment , Risk Factors , Saphenous Vein/diagnostic imaging , Saphenous Vein/physiopathology , Time Factors , Treatment Outcome , Vascular Patency
10.
J Interv Cardiol ; 31(6): 939-948, 2018 Dec.
Article in English | MEDLINE | ID: mdl-30318677

ABSTRACT

BACKGROUND: Post-myocardial infarction (MI) ventricular septal defects (PIVSD) are an uncommon but life-threatening complication of acute MI. Although surgical closure has been the standard of care, mortality, and recurrence of VSD remain high even after emergent surgery. Transcatheter VSD closure (TCC) devices have become an alternative or adjunct to surgical closure. METHODS: Online database search was performed for studies that included adults with PIVSD who underwent medical treatment (MT) alone, surgical closure (SC) (early or late), and TCC (early, late, or for post-surgical residual VSD). RESULTS: Twenty-six studies were included with a total of 737 patients who underwent either MT (N = 100), SC (early (n = 167), late (n = 100)), and TCC (early (n = 176), late (n = 115), or post-surgical residual VSD (n = 79)). The 30-day mortality among MT group was 92 ± 6.3%, among SC was 61 ± 22.5% (early 56 ± 23%, late 41 ± 30%), and for all TCC patients was 33 ± 24% (early 54 ± 32.7%, late 16 ± 26%), and TCC for post-surgical residual VSD 11 ± 34.9%. The mortality among overall SC, overall TCC and early TCC groups was significantly lower as compared with the MT (P < 0.001 for all comparisons). The overall mortality among all TCC, and late TCC groups was significantly lower when compared with the late SC (P < 0.0001, P < 0.0001, respectively). CONCLUSION: Closure of PIVSD decreases mortality as compared with MT alone and should be attempted as early as possible after diagnosis. Selection of TCC versus SC should be based on factors including complexity of the defect, availability of closure devices, expertise of the operator, and clinical condition of patient.


Subject(s)
Cardiac Surgical Procedures/statistics & numerical data , Heart Septal Defects, Ventricular/therapy , Myocardial Infarction/complications , Septal Occluder Device/statistics & numerical data , Adult , Aged , Heart Septal Defects, Ventricular/etiology , Heart Septal Defects, Ventricular/mortality , Humans , Middle Aged , Myocardial Infarction/mortality , Myocardial Infarction/therapy , Survival Rate , Treatment Outcome
12.
Circ Cardiovasc Interv ; 10(12)2017 Dec.
Article in English | MEDLINE | ID: mdl-29246912

ABSTRACT

BACKGROUND: Current guidelines give a class I recommendation to use of embolic protection devices (EPD) for saphenous vein graft (SVG) intervention; however, studies have shown conflicting results. The objective of this meta-analysis is to compare all-cause mortality, major adverse cardiovascular events, myocardial infarction (MI), or target vessel revascularization in SVG intervention with and without EPD. METHODS AND RESULTS: Literature was searched through October 2016. Eight studies (n=52 893) comparing SVG intervention performed with EPD (n=11 506) and without EPD (n=41 387) were included. There was no significant difference in all-cause mortality (odds ratio [OR], 0.79; confidence interval [CI], 0.55-1.12; P=0.19), major adverse cardiovascular events (OR, 0.73, CI, 0.51-1.05; P=0.09), target vessel revascularization (OR, 1.0; CI, 0.95-1.05; P=0.94), periprocedural MI (OR, 1.12; CI, 0.65-1.90, P=0.69), and late MI (OR, 0.80; CI, 0.52-1.23; P=0.30) between the 2 groups. Sensitivity analysis excluding CathPCI Registry study showed no difference in periprocedural MI, late MI, and target vessel revascularization; however, it favored EPD use in all-cause mortality and major adverse cardiovascular events. Further sensitivity analysis including only observational studies revealed no difference in all-cause mortality, major adverse cardiovascular events, target vessel revascularization, and late MI. Additional analysis after excluding CathPCI Registry study revealed no difference in outcomes. CONCLUSIONS: This study including 52 893 patients suggests no apparent benefit in routine use of EPD during SVG intervention in the contemporary real-world practice. Further randomized clinical trials are needed in current era to evaluate long-term outcomes in routine use of EPD, and meanwhile, current guideline recommendations on EPD use should be revisited.


Subject(s)
Coronary Artery Bypass/adverse effects , Coronary Artery Disease/surgery , Embolic Protection Devices , Graft Occlusion, Vascular/therapy , Percutaneous Coronary Intervention/instrumentation , Saphenous Vein/transplantation , Aged , Aged, 80 and over , Chi-Square Distribution , Coronary Artery Bypass/mortality , Coronary Artery Disease/mortality , Female , Graft Occlusion, Vascular/etiology , Graft Occlusion, Vascular/mortality , Graft Occlusion, Vascular/physiopathology , Humans , Male , Middle Aged , Myocardial Infarction/etiology , Myocardial Infarction/mortality , Odds Ratio , Percutaneous Coronary Intervention/adverse effects , Percutaneous Coronary Intervention/mortality , Prosthesis Design , Risk Factors , Saphenous Vein/physiopathology , Time Factors , Treatment Outcome , Unnecessary Procedures
13.
Am J Med Sci ; 354(3): 291-298, 2017 09.
Article in English | MEDLINE | ID: mdl-28918837

ABSTRACT

BACKGROUND: The objective of this study is to determine the diagnostic performance of computed tomography perfusion (CTP) with and without computed tomography angiography (CTA) in assessment of hemodynamically significant coronary artery lesions in comparison to invasive fractional flow reserve (FFR). MATERIALS AND METHODS: PubMed and Cochrane Center Register of Controlled Trials from January 2010 searched through December 2014. Nine original studies were selected evaluating the diagnostic performance of CTP with and without CTA to invasive coronary angiography in evaluation of hemodynamic significance of coronary lesions (n = 951). RESULTS: The sensitivity, specificity, LR+ and LR- and DOR of CTA+CTP were 0.85 [95% confidence interval (CI: 0.79-0.89)] 0.94 (CI: 0.91-0.97), 15.8 (CI: 7.99-31.39), 0.146 (CI: 0.08-0.26), and 147.2 (CI: 69.77-310.66). Summary Receiver Operating Characteristics (SROC) results showed area under the curve (AUC) of 0.97 indicating that CTA+CTP may detect hemodynamically significant coronary artery lesions with high accuracy. The sensitivity, specificity, LR+ and LR- and DOR of CTP were 0.83 (CI: 0.78-0.87), 0.84 (CI: 0.80-0.87) 5.26 (CI: 2.93-9.43), 0.209 (CI: 0.12-0.36), and 31.97 (CI: 11.59-88.20). CONCLUSIONS: This result suggests that CTP with CTA significantly improves diagnostic performance of coronary artery lesions compared to CTA alone and closely comparable with invasive FFR.


Subject(s)
Computed Tomography Angiography/methods , Coronary Angiography/methods , Coronary Artery Disease/diagnostic imaging , Coronary Vessels/diagnostic imaging , Hemodynamics/physiology , Myocardial Perfusion Imaging/methods , Coronary Artery Disease/physiopathology , Coronary Vessels/physiopathology , Humans , Sensitivity and Specificity
14.
South Med J ; 110(2): 90-96, 2017 02.
Article in English | MEDLINE | ID: mdl-28158877

ABSTRACT

OBJECTIVES: The central Appalachian region of the United States is disproportionately burdened with cardiovascular diseases (CVD) and associated risk factors; however, research to inform clinical practice and policies and programs is sparse. This study aimed to examine the association between multiple modifiable risk factors for CVD and hypertension in asymptomatic patients in central Appalachia. METHODS: Between January 2011 and December 2012, 1629 asymptomatic individuals from central Appalachia participated in screening for subclinical atherosclerosis. Participants were asked to report their hypertension status (yes/no). In addition, data on two nonmodifiable risk factors (sex, age) and five modifiable risk factors (obesity, diabetes mellitus, hypercholesterolemia, smoking, and sedentary lifestyle) were collected. Multivariable logistic regression analyses were conducted to assess association between hypertension and risk factors. RESULTS: Of the 1629 participants, approximately half (49.8%) had hypertension. Among people with hypertension, 31.4% were obese and 62.3% had hypercholesterolemia. After adjusting for sex and age, obesity and diabetes mellitus were associated with a more than twofold increased odds of having hypertension (odds ratio [OR] 2.02, confidence interval [CI] 1.57-2.60 and OR 2.30, CI 1.66-3.18, respectively). Hypercholesterolemia and sedentary lifestyle were associated with higher odds for hypertension (OR 1.26, CI 1.02-1.56 and OR 1.38, CI 1.12-1.70, respectively), compared with referent groups. Having two, three, and four to five modifiable risk factors was associated with increased odds of having hypertension by about twofold (OR 1.72, CI 1.21-2.44), 2.5-fold (OR 2.55, CI 1.74-3.74), and sixfold (OR 5.96, CI 3.42-10.41), respectively. CONCLUSIONS: This study suggests that the odds of having hypertension increases with a higher number of modifiable risk factors for CVD. As such, implementing an integrated CVD program for treating and controlling modifiable risk factors for hypertension would likely decrease the future risk of CVD.


Subject(s)
Cardiovascular Diseases , Hypertension/epidemiology , Adult , Aged , Appalachian Region/epidemiology , Asymptomatic Diseases/epidemiology , Cardiovascular Diseases/epidemiology , Cardiovascular Diseases/prevention & control , Cardiovascular Diseases/psychology , Diabetes Mellitus/epidemiology , Effect Modifier, Epidemiologic , Female , Humans , Hypercholesterolemia/epidemiology , Male , Middle Aged , Obesity/epidemiology , Prevalence , Risk Factors , Sedentary Behavior , Smoking/epidemiology
15.
Curr Cardiol Rep ; 19(2): 12, 2017 02.
Article in English | MEDLINE | ID: mdl-28185168

ABSTRACT

PURPOSE OF REVIEW: Patients with stable coronary artery disease (CAD) and a high risk of bleeding are not ideal candidates for a polymer-based drug-eluting stent (DES) because it requires 6-12 months of dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI). The purpose of this review is to assess the angiographic and clinical outcomes of polymer-free drug-coated stents (PF-DCS) in stable CAD patients with a high bleeding risk. RECENT FINDINGS: Several randomized controlled trials (RCTs) have compared angiographic and clinical outcomes of PF-DCS with bare-metal stents (BMS), permanent polymer (PP)-DES, or biodegradable polymer (BP)-DES. However, none of these studies particularly recruited patients with stable CAD and a high risk of bleeding. Furthermore, there are limited data available on duration of DAPT following PF-DCS placement. PF-DCS has a better efficacy and similar safety as compared with BMS. PF-DCS with dual drug is noninferior to currently available PP-DES. Further RCTs are needed to assess the safety and efficacy of PF-DCS to BP-DES and PP-DES comparing shorter to standard durations of DAPT.


Subject(s)
Coronary Artery Disease/therapy , Drug-Eluting Stents , Percutaneous Coronary Intervention , Platelet Aggregation Inhibitors/administration & dosage , Coronary Thrombosis/etiology , Hemorrhage/etiology , Humans , Polymers/chemistry , Randomized Controlled Trials as Topic , Risk Factors , Treatment Outcome
16.
J Investig Med High Impact Case Rep ; 5(1): 2324709617692833, 2017.
Article in English | MEDLINE | ID: mdl-28210642

ABSTRACT

Hereditary hemorrhagic telangiectasia (HHT), also known as Osler-Weber-Rendu syndrome, is a rare genetic blood disorder that leads to abnormal bleeding due to absent capillaries and multiple abnormal blood vessels known as arteriovenous malformations. A feature of HHT is high-output heart failure due to multiple arteriovenous malformations. High-output heart failure can lead to recurrent epistaxis Kiesselbach area syndrome (REKAS), further exacerbating heart failure through increased blood loss and resultant anemia. We report a patient with HHT who presented with high-output heart failure contributing to REKAS. In patients with REKAS, we propose if anemia is present, REKAS can be avoided by correcting the anemia by increasing the hemoglobin level to greater than 9 to 10 g/dL. This decreases hyperdynamic circulation and reduces pressure in the blood vessels of the nose.

17.
Am J Med Sci ; 352(3): 306-13, 2016 Sep.
Article in English | MEDLINE | ID: mdl-27650237

ABSTRACT

OBJECTIVE: Studies have shown that iodinated radiocontrast use is associated with acute renal failure especially in the presence of chronic kidney disease and multiple factors modulate this risk. The purpose of this meta-analysis is to compare the incidence of renal failure requiring hemodialysis between transfemoral (TF) and transapical (TA) transcatheter aortic valve replacement using the Edwards valve. METHODS: The PubMed database was searched from January 2000 through December 2014. A total of 10 studies (n = 2,459) comparing TF (n = 1,268) and TA (n = 1,191) TAVR procedures using the Edwards valve were included. Variables of interest were baseline logistic EuroSCORE, prevalence of diabetes mellitus, hypertension, peripheral arterial disease, chronic kidney disease and amount of contrast used. The primary endpoint was incidence of renal failure requiring hemodialysis. The odds ratio and 95% CI were computed and P < 0.05 was considered as the level of significance. RESULTS: The logistic EuroSCORE was significantly higher in TA compared to TF (P = 0.001) TAVR. The amount of contrast (mL) used was significantly higher in the TF group compared to the TA group (mean difference: 36.9, CI: 25.7-48.1, P < 0.001). The incidence of hemodialysis following the procedure was significantly higher in the TA group compared to TF group (odds ratio = 4.3, CI: 2.4-7.8, P < 0.00001). CONCLUSIONS: This meta-analysis suggests that despite the lower amount of contrast used in TA-TAVR, the incidence of renal failure requiring hemodialysis was higher with the Edwards valve. This suggests that the incidence of renal failure requiring hemodialysis after TAVR is associated with baseline comorbidities in the TA-TAVR group rather than the volume of contrast used.


Subject(s)
Acute Kidney Injury/etiology , Heart Valve Prosthesis , Renal Replacement Therapy , Transcatheter Aortic Valve Replacement/adverse effects , Transcatheter Aortic Valve Replacement/methods , Acute Kidney Injury/epidemiology , Humans , Incidence
18.
Am J Med Sci ; 352(2): 219-22, 2016 08.
Article in English | MEDLINE | ID: mdl-27524223

ABSTRACT

Cardiovascular disease in populations with obesity is a major concern because of its epidemic proportion. Obesity leads to the development of cardiomyopathy directly via inflammatory mediators and indirectly by obesity-induced hypertension, diabetes and coronary artery diseases. The aim of this review article is to re-visit the available knowledge and the evidence on pathophysiologic mechanisms of obesity-related cardiomyopathy and to propose its placement into a specific category of myocardial disease.


Subject(s)
Cardiomyopathies/epidemiology , Cardiomyopathies/physiopathology , Heart Failure/epidemiology , Heart Failure/physiopathology , Obesity/epidemiology , Obesity/physiopathology , Animals , Cardiomyopathies/blood , Heart Failure/blood , Humans , Insulin Resistance/physiology , Obesity/blood
19.
J La State Med Soc ; 168(2): 57-9, 2016.
Article in English | MEDLINE | ID: mdl-27383857

ABSTRACT

Unicuspid aortic valve (UAV), which is a rare congenital anomaly, usually presents as aortic stenosis and/or aortic regurgitation. Here we present a case of UAV co-existent with an ascending aortic aneurysm. A 26-year-old male with no significant past medical history presented to the hospital after two episodes of syncope. Transthoracic echocardiogram showed an ejection fraction of 62%, severely stenotic aortic valve, and moderate aortic regurgitation. Computed tomography revealed calcification of the aortic valve, compatible with aortic stenosis and aneurysm of the ascending aorta measuring 4.3 cm in diameter. He underwent successful aortic valve replacement and repair of ascending aortic aneurysm. He recovered well without any complications. This case suggests that any young patient who presents with syncope, aortic stenosis would be a differential and further workup by any available non-invasive modality needs to be performed.


Subject(s)
Aortic Aneurysm/diagnostic imaging , Aortic Valve/abnormalities , Adult , Aortic Aneurysm/complications , Aortic Valve/diagnostic imaging , Aortic Valve/surgery , Aortic Valve Stenosis/etiology , Diagnosis, Differential , Echocardiography, Doppler , Echocardiography, Transesophageal , Humans , Male , Syncope/etiology
20.
J Cardiovasc Med (Hagerstown) ; 17(9): 694-700, 2016 Sep.
Article in English | MEDLINE | ID: mdl-27472038

ABSTRACT

AIMS: Noninvasive fractional flow reserve (FFR) measurement with computed tomography (FFRCT) is a newly described method for assessing functional significance of coronary disease. The objective of this meta-analysis is to determine the diagnostic performance of FFRCT in the assessment of hemodynamically significant coronary artery stenosis. METHODS: PubMed and the Cochrane Center Register of Controlled Trials were searched from January 2000 through February 2015. Six original studies were found comparing FFRCT to invasive FFR in evaluating hemodynamic significance of coronary lesions (1354 vessels; 812 patients). Lesions were considered hemodynamically significant if invasive FFR was 0.80 or less. FFRCT used the same cutoff as invasive FFR to be considered as a positive test. Sensitivity, specificity, positive and negative likelihood ratios, and diagnostic odds ratio were calculated. RESULTS: One-third of the lesions (n = 443) were hemodynamically significant. The pooled per-vessel analysis showed that the sensitivity, specificity, negative and positive likelihood ratios, and diagnostic odds ratio of FFRCT to diagnose hemodynamically significant coronary disease were 0.84 [95% confidence interval (CI): 0.80-0.87], 0.76 (95% CI: 0.73-0.79), 0.22 (95% CI: 0.17-0.29), 3.48 (95% CI: 2.21-5.47), and 16.82 (95% CI: 8.20-34.49), respectively. CONCLUSION: The results of this meta-analysis demonstrate that FFRCT results correlate closely with invasive coronary angiography and FFR measurement. It is a feasible noninvasive method to assess hemodynamic significance of coronary lesions in patients with stable coronary artery disease.


Subject(s)
Coronary Artery Disease/diagnostic imaging , Fractional Flow Reserve, Myocardial/physiology , Coronary Angiography/methods , Coronary Artery Disease/physiopathology , Humans , Sensitivity and Specificity , Tomography, X-Ray Computed/methods
SELECTION OF CITATIONS
SEARCH DETAIL
...